Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs
The social networking site for doctors also plans to expand to its first Spanish-speaking country next month.
The health insurance industry's trade association, along with other organizations, sent a letter to the FDA arguing that different names could lead to prescriber confusion and medication errors.
Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME
Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol
The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.
Havas Health adds PR agency Just:: Health Communications in bid to expand its global footprint.
A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again
Supreme Court affirmed the legality of the Affordable Care Act for a second time on Thursday
Fourth and fifth members of network add healthcare advertising and PR expertise.
AbbVie says curative effects hold whether Viekira Pak used with or without ribavirin; House Republicans vote to eliminate IPAB; analyst sets high price target for Alexion.
The consumer-insights firm said it's debuting a listening feature that will make it harder for pharma to ignore Twitter, Reddit and the other big social platforms.
The promise of an Opdivo/Yervoy combination, now awaiting FDA approval, has more to do with payer strategy than efficacy, analysts say.
Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill
Clinical trial results for experimental antidotes to oral anticoagulants Pradaxa and Eliquis indicate they reverse blood thinners in a short time.
AstraZeneca, DigitasLBI New York take top prize in pharma category at Cannes Lions Health; Teva buys a stake in Mylan; Shire tops pharma reputation survey.
The inspirational value is clear for Lions Health attendees, but there is still confusion about what good looks like for branded pharma campaigns, and how the US fits in.
It's not only a venue to gain creative inspiration, but a good place to scout talent, and there are no lack of strategic meetings underway in Cannes.
Mobile app makers shared insights about how to improve people's health and change behavior at the Lions Health festival.
The second annual Lions Health creativity festival ended Saturday.
It's not always regulation or concerns about legal risks. Sometimes, a drugmaker's internal conservative culture is the biggest hurdle to overcome.
AstraZeneca's "Take it from a Fish" took the top prize.
Teva loses Copaxone patent suit; Oncologists at Memorial Sloan Kettering Cancer Center developed cancer drug cost calculator; Bayer will invest $4.5 billion in R&D in the coming year.
The Lions Health award winners will be announced later Friday at an event in Cannes, France.
The health benefits exchange also retained Ogilvy Public Relations for its $2-million-a-year communications account, PRWeek reported.
Its alliance with the Society of Hospital Medicine will expand the network's reach among medical professionals.
The activity monitor dominates the fitness market, but competition in the overall health category is increasing.
The Japan-based drugmaker recast its global organization in hopes of ensuring that emerging molecules make a smoother transition to market.
The effort is part of the consultancy's Startup Challenge that pairs health neophytes with mentors.
Merck settles a marketing lawsuit for $5.9 million; CVS plans to create diagnostic apps; a survey shows advertising agencies plan to keep head count steady for the rest of the year
Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute signed on to help the drugmaker develop cancer treatments.
Drugmakers, experts discuss strategies to cope with costly new drugs.
Allergan acquires double-chin treatment manufacturer, Kythera, for $2.1 billion; Valeant eyes acquisition of Egyptian drugmaker; worldwide drug sales could reach $1 trillion by 2020
A dive into financial relationships between industry and doctors showed women receive less money for research, education and speaking than men.
Speakers at Klick Health's event criticized, lauded the role of technology in healthcare.
The drugmaker and university will work together to develop new treatments for eye-related diseases like age-related macular degeneration.
Novo Nordisk replaces Sanofi as the top marketer of metabolic drugs; Actavis changed its name to Allergan; access to Medicare Part D has not reduced overall Medicare costs
The Medical Information Working Group and the Washington Legal Foundation filed briefs in support of Amarin.
Cardiologists are more likely to prescribe the experimental drugs than are primary-care physicians.
CVS Health to buy Target's pharmacy business; experimental gene therapy improves condition of teen with sickle-cell disease; PatientsLikeMe partners with the FDA to improve postmarket surveillance
PhRMA files amicus brief in support of Amarin's off-label lawsuit; Public Citizen argues FDA wrongly expanded indication for Hetlioz; FDA panel recommends GSK's new asthma treatment for approval
An FDA letter says there was no need to go to court but experts tell MM&M this lawsuit highlights an issue that is bigger than a single pill.
A data-mining analysis of patient records found a significant increase in the chance of heart attack for those taking proton-pump inhibitors.
Los Angeles County voted in favor of adding the drug to the public health program's repertoire in fighting HIV and AIDS.
Amgen's PCSK9 inhibitor is the second in its class to get an FDA panel endorsement; a new drug could threaten Shire's hold on a rare-disease category; a study shows pharma invests less in Hispanic audiences than in other groups
Medscape marked its 20th anniversary with a reunion this week that attracted staffers from the portal's earliest days.
The three-year-old campaign's youthful tone evolves as its audience ages.
Roche's Actemra is already approved for three forms of arthritis.
FDA panel recommends Sanofi/Regeneron's PCSK9 inhibitor for approval; Merck and Samsung collaboration says their rheumatoid arthritis biosimilars are equivalent to the biologic versions; Bayer offloads its diabetes-care business
An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.
There has been little talk about mepolizumab but an approval would fill out GSK's flagging respiratory category.
The drugmaker's once-daily diabetes treatment, lixisenatide, will be sent back to US regulators after Sanofi pulled the submission in 2013 to finish a cardiovascular outcomes trial.
Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids
An FDA advisory committee will sound off on the future of cholesterol-lowering treatments this week, discussing if Sanofi/Regeneron's Praluent and Amgen's Repatha warrant marketing approval.
Jed Savage replaces Scott Wolf.
Concerns persist regarding the drug's impact on liver enzymes and fat.
Novartis CEO says pharma must regulate itself; Shire reportedly is in talks to buy biotech Actelion; Lilly insulin outperforms Lantus although safety concerns remain
FDA panel recommends approval of female Viagra; FDA says that Sanofi's and Regeneron's PCSK9 inhibitor lowers LDL; GSK cuts 350 jobs
Havas Health developed the inhaled insulin's advertising campaign, which is slated to kick off later this summer.
UK indie shop buys healthcare specialist agency to strengthen media-planning business.
Genzyme's experimental enzyme-replacement therapy olipudase alfa is being investigated for the Type B form of the condition.
Novartis appeals the ban on its biosimilar Zarxio; AbbVie petitions for distinct biosimilar labels; Sanofi will study Toujeo in a real-world setting
Employer-insured enrollees spend more on prescriptions than health-insurance exchange enrollees, but the groups spend the same amount of money when it comes to specialty medications, a study shows.
Teva is planning to up its stake in Mylan prior to a possible legal challenge; Perrigo acquires GSK OTC portfolio; Express Scripts considers creative ways to drive down drug costs
The new initiative, ATDigitalHealth, will help healthcare companies with disruptive concepts win over decision-makers.
An inVentiv Health study indicates patient groups want more say in drug development and patient support.
The academic partnership builds on the company's 2014 collaboration with UCB on using sensors to gather biometric data about people with neurological disorders.
A House committee is looking into the FDA's warning letter publication process; Amgen and Roche collaborate on cancer combination drug; study shows online health information fails teenagers
The first of seven games aimed at teaching about immuno-oncology lets players fling antibodies at cancer cells.
The new OTC medication almost hit $100 million in sales in its first 16 weeks on the market.
Bristol-Myers Squibb's Opdivo serves up lukewarm lung-cancer results; new cancer drugs are too expensive, Sloan Kettering oncologist tells ASCO attendees; Teva settlement could stymie industry use of pay-for-delay patent tactics
Amgen prepares for pricing battle over PCSK9-inhibitor Repatha; Otsuka loses Abilify lawsuit; healthcare and pharma marketers will boost spending on digital advertising in 2015
Teva reached a settlement with the Federal Trade Commission to resolve an antitrust suit that charged the drugmaker's subsidiary Cephalon with illegally blocking generic competition for narcolepsy drug Provigil.
The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate
The updated app now tracks everyday health metrics including weight, activity and glucose levels.
The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.
The test seeks to identify patients with metastatic pancreatic cancer and high levels of hyaluronan.
Rep. Billy Long introduced legislation that is meant to push the FDA to implement clearer guidelines for regulating drug product information on social media.
Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill
Twenty states now allow nurse practitioners to practice without an MD affiliation.
A horse race between Merck and Bristol-Myers Squibb, and the importance of one biomarker, will be a focus at the American Society of Clinical Oncology's annual meeting.
An appeals court affirmed an earlier ruling that Actavis must keep an older formulation of its Alzheimer's drug, Namenda, on the market.
The review does not include North America, the healthcare giant said.
Experimental psoriasis drug linked to suicidal thoughts; analysis finds that some high prescribers receive non-research industry money; researchers say new MS drugs spur higher prices of older medications
Amgen's PSCK9 inhibitor gets a position opinion in the EU; the FDA plans to study how spouses influence perception of DTC ads; Botox may relieve depression
The legislation would allow drugmakers to share economic information with payers beyond what is included on the FDA-approved label.
The FDA's advertising division said images and copy for the BPH drug Rapaflo are misleading.
Researchers say Twitter could provide critical insight into health needs for hard-to-reach groups.
CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year
The West Coast independent agency redefined its leadership team with the appointments of founding principal Steven Gold as CEO and Jeff Nemy as CFO.
The FDA's bad-ad group said the banner they saw at a professional conference was misleading.
FDA official says DTC risk claims are a waste of time; one analyst believes Afrezza could turn around sluggish sales; J&J inks billion-dollar deal to commercialize HCV drugs
The new Centron includes renamed medical education, public relations and market access divisions.
McNeil Consumer Healthcare president Denice Torres was named woman of the year by the Healthcare Businesswomen's Association.
Parties in the effort say the novelty of wearing an Apple Watch, along with a newly developed app, may help clinicians refine treatment plans and patient support.
Perrigo says a Mylan deal is possible; new guidelines may reduce cancer screenings; Takeda petitions dictionaries to add a new definition for depression
Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.
Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition
Long-time practice lead Gil Bashe is tasked with unifying and building the health function at global firm Finn Partners.
Genentech alums launch a new biotechnology company; Mallinckrodt sues the FDA over a drug reclassification; Sanofi takes on celiac disease
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.